Integra’s DuraSeal® Dural Sealant Saves Healthcare Costs According to an Economic Evaluation Published in the Journal of Comparative Effectiveness Research

PRINCETON, N.J., Nov.

13, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the publication of a new economic study, “PEG hydrogel sealant versus fibrin glue in posterior fossa surgery: An economic comparison across five European countries.” 1 The purpose of this evaluation was to assess the budget-impact of switching patient treatment from fibrin glue to DuraSeal Polyethylene Glycol (PEG) hydrogel in five major European countries: Belgium, France, Germany, Italy, and the United Kingdom. The evaluation demonstrates an average cost savings of €419 to €1,279 per patient, when using Integra’s DuraSeal PEG dural sealant hydrogel instead of fibrin glue.

Depending on the country, consistent cost reduction per procedure averaged around 22%, except for Italy where the analysis resulted in 15% consistent cost reduction per procedure. Cerebrospinal fluid (CSF) leaks after posterior cranial fossa (PCF) surgery are a significant cause of longer hospital stays, hospital readmissions and other costly post-surgical interventions. Current practice to seal the operative site after primary closure aid the healing process and protect the patient from CSF leaks widely relies on either fibrin glue or PEG hydrogel.

2 The analysis, published in the Journal of Comparative Effectiveness Research in February 2024, was conducted by Giuseppe Talamonti 3 , Jorn-Andre Horaczek 4 , Rafael Torrejon Torres.